JP2014512364A - 水溶液中で二量体化できる単量体、およびその使用法 - Google Patents

水溶液中で二量体化できる単量体、およびその使用法 Download PDF

Info

Publication number
JP2014512364A
JP2014512364A JP2014504078A JP2014504078A JP2014512364A JP 2014512364 A JP2014512364 A JP 2014512364A JP 2014504078 A JP2014504078 A JP 2014504078A JP 2014504078 A JP2014504078 A JP 2014504078A JP 2014512364 A JP2014512364 A JP 2014512364A
Authority
JP
Japan
Prior art keywords
substituted
monomer
group
alkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014504078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014512364A5 (enExample
Inventor
フランシス バラニー
マニッシュ ピングル
ドナルド イー． ベルイストローム
サラ フィリッパ ジャルディーナ
リー ダニエル アーノルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2014512364A publication Critical patent/JP2014512364A/ja
Publication of JP2014512364A5 publication Critical patent/JP2014512364A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2014504078A 2011-04-07 2012-04-09 水溶液中で二量体化できる単量体、およびその使用法 Pending JP2014512364A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473093P 2011-04-07 2011-04-07
US61/473,093 2011-04-07
PCT/US2012/032809 WO2013058824A1 (en) 2011-04-07 2012-04-09 Monomers capable of dimerizing in an aqueous solution, and methods of using same

Publications (2)

Publication Number Publication Date
JP2014512364A true JP2014512364A (ja) 2014-05-22
JP2014512364A5 JP2014512364A5 (enExample) 2015-05-28

Family

ID=48141232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014504078A Pending JP2014512364A (ja) 2011-04-07 2012-04-09 水溶液中で二量体化できる単量体、およびその使用法

Country Status (4)

Country Link
US (2) US20140194383A1 (enExample)
EP (1) EP2694707B1 (enExample)
JP (1) JP2014512364A (enExample)
WO (1) WO2013058824A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021017438A (ja) * 2019-07-17 2021-02-15 信越化学工業株式会社 ジメチルシクロブタン環を有するジエステル化合物及びその製造方法、並びにそれから誘導されるジメチルシクロブタン化合物の製造方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
JP2014511865A (ja) 2011-04-07 2014-05-19 コーネル ユニバーシティー 水溶液中で多量化できるシリル単量体、およびその使用法
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
MX356059B (es) 2013-01-30 2018-05-11 Dow Agrosciences Llc Uso de benzoxaboroles como agentes antimicrobianos volatiles en carnes, plantas, o partes de plantas.
CN103880679B (zh) * 2014-03-13 2015-02-11 河北科技大学 3-乙氧基-4-乙氧羰基苯乙酸的合成方法
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
WO2016115360A1 (en) * 2015-01-14 2016-07-21 Coferon, Inc. C-myc ligands capable of dimerizing in an aqueous solution, and methods of using same
WO2016183359A1 (en) 2015-05-12 2016-11-17 Blinkbio, Inc. Silicon based drug conjugates and methods of using same
GB201603359D0 (en) * 2016-02-26 2016-04-13 Binding Site Group The Ltd Improved assay
EP3426029B1 (en) 2016-03-07 2023-08-30 AgroFresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
CN109475567A (zh) 2016-06-09 2019-03-15 布兰克生物股份有限公司 基于硅烷醇的治疗有效载荷
CN107573297A (zh) * 2017-08-31 2018-01-12 桂林南药股份有限公司 一种利奈唑胺的酸性水解杂质的制备方法
CN109678701B (zh) * 2019-01-22 2021-08-20 安徽德信佳生物医药有限公司 一种维兰特罗中间体的制备方法
ES2951876T3 (es) * 2019-07-17 2023-10-25 Shinetsu Chemical Co Compuesto diéster que tiene un anillo de dimetilciclobutano, un procedimiento para preparar el mismo, y un procedimiento para preparar compuesto de dimetilciclobutano derivado del compuesto diéster
JP2023510109A (ja) * 2019-12-20 2023-03-13 アルブータス・バイオファーマー・コーポレイション 合成プロセス及び中間体
CA3186944A1 (en) * 2020-08-07 2022-02-10 Francis Barany Therapeutic composition of cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and usage
WO2022031777A2 (en) * 2020-08-07 2022-02-10 Cornell University Therapeutically useful cure-pro molecules for e3 ligase mediated degradation of proteins, and methods of making and using them
CN114315787A (zh) * 2021-12-30 2022-04-12 广州佳途科技股份有限公司 一种维兰特罗ep杂质2的制备方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510697A (ja) * 2000-05-22 2004-04-08 アベンティス・ファーマスーティカルズ・インコーポレイテツド トリプターゼ阻害剤として使用するためのアリールメチルアミン誘導体
WO2009067202A1 (en) * 2007-11-21 2009-05-28 Janssen Pharmaceutica, N.V. Spiropiperidines for use as tryptase inhibitors
WO2009126290A2 (en) * 2008-04-09 2009-10-15 Cornell University Coferons and methods of making and using them
JP2010534836A (ja) * 2007-07-27 2010-11-11 アンサンブル ディスカバリー コーポレイション 検出アッセイとそれらの使用
WO2011022449A1 (en) * 2009-08-20 2011-02-24 Sanofi-Aventis Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63222153A (ja) 1987-03-11 1988-09-16 Kanegafuchi Chem Ind Co Ltd 新規α−シアノケイ皮酸アミド誘導体
US5236919A (en) 1989-02-28 1993-08-17 Imperial Chemical Industries Plc Quinoxalinyl derivatives suitable for use in leukotriene mediated disease
WO1998054255A1 (en) 1997-05-30 1998-12-03 Shiseido, Co., Ltd. Copolymer containing reactive silyl groups, composition containing the same, and method of treatment with the same
CA2270233A1 (en) 1997-09-05 1999-03-18 Matsushita Electric Industrial Co., Ltd. Fluorescence polarization method
US6326478B1 (en) 1998-07-08 2001-12-04 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
MXPA02011400A (es) 2000-05-22 2003-05-23 Aventis Pharm Prod Inc Derivados de arimetilamina para uso como inhibidores de triptasa.
GB0111459D0 (en) 2001-05-10 2001-07-04 Isis Innovation Universal fluorescent sensors
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
JP3841398B2 (ja) 2001-12-17 2006-11-01 富士写真フイルム株式会社 ネガ型レジスト組成物
US20040241748A1 (en) 2003-02-10 2004-12-02 Dana Ault-Riche Self-assembling arrays and uses thereof
EP1723159B1 (en) 2004-02-27 2019-06-12 Melinta Therapeutics, Inc. Macrocyclic compounds and methods of making and using the same
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
TW200800201A (en) 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
EP1961750B1 (en) 2005-12-13 2013-09-18 Daiichi Sankyo Company, Limited Vla-4 inhibitory drug
CA2631777A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
US20080255403A1 (en) 2007-04-13 2008-10-16 Ethicon Endo-Surgery, Inc. Magnetic nanoparticle therapies
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
WO2009076373A1 (en) 2007-12-10 2009-06-18 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
EP2485678A4 (en) 2009-10-07 2013-04-03 Univ Cornell Coferons and methods of making and using them
US20140161729A1 (en) 2011-04-07 2014-06-12 Cornell University Cofluorons and methods of making and using them
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
JP2014511865A (ja) 2011-04-07 2014-05-19 コーネル ユニバーシティー 水溶液中で多量化できるシリル単量体、およびその使用法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510697A (ja) * 2000-05-22 2004-04-08 アベンティス・ファーマスーティカルズ・インコーポレイテツド トリプターゼ阻害剤として使用するためのアリールメチルアミン誘導体
JP2010534836A (ja) * 2007-07-27 2010-11-11 アンサンブル ディスカバリー コーポレイション 検出アッセイとそれらの使用
WO2009067202A1 (en) * 2007-11-21 2009-05-28 Janssen Pharmaceutica, N.V. Spiropiperidines for use as tryptase inhibitors
WO2009126290A2 (en) * 2008-04-09 2009-10-15 Cornell University Coferons and methods of making and using them
WO2011022449A1 (en) * 2009-08-20 2011-02-24 Sanofi-Aventis Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARBOHYDRATE RESEARCH, vol. 309, no. 1, JPN6016042022, 1998, pages 31 - 38, ISSN: 0003430457 *
CARBOHYDRATE RESEARCH, vol. 95, no. 1, JPN6016042026, 1981, pages 1 - 26, ISSN: 0003430459 *
JOURNAL OF CHROMATOGRAPHY B, vol. Vol.869, No.1-2, JPN6016042024, 2008, pages 45 - 53, ISSN: 0003430458 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021017438A (ja) * 2019-07-17 2021-02-15 信越化学工業株式会社 ジメチルシクロブタン環を有するジエステル化合物及びその製造方法、並びにそれから誘導されるジメチルシクロブタン化合物の製造方法
JP7335849B2 (ja) 2019-07-17 2023-08-30 信越化学工業株式会社 ジメチルシクロブタン環を有するジエステル化合物及びその製造方法、並びにそれから誘導されるジメチルシクロブタン化合物の製造方法

Also Published As

Publication number Publication date
WO2013058824A1 (en) 2013-04-25
US11970448B2 (en) 2024-04-30
US20140194383A1 (en) 2014-07-10
EP2694707A4 (en) 2014-09-10
EP2694707A1 (en) 2014-02-12
US20200354319A1 (en) 2020-11-12
EP2694707B1 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
JP2014512364A (ja) 水溶液中で二量体化できる単量体、およびその使用法
JP6035347B2 (ja) 三環式スルホンアミド化合物ならびにその作製および使用方法
JP6757709B2 (ja) 水溶液中で多量化できるシリル単量体、およびその使用法
JP2005538062A (ja) 化合物、組成物、および方法
CN105339350B (zh) 二氢吡啶酮mgat2抑制剂
JP2017538678A (ja) 免疫調節剤
JP2010531875A (ja) イミダゾピリジニルチアゾリルヒストンデアセチラーゼ阻害剤
JP2015509102A (ja) 三環式スルホン化合物並びにその作製および使用方法
TW201329048A (zh) 芳基二氫吡啶酮及六氫吡啶酮ｍｇａｔ２抑制劑
TW200404060A (en) Fused heterocyclic compounds
WO2016115360A1 (en) C-myc ligands capable of dimerizing in an aqueous solution, and methods of using same
US20220280488A1 (en) Pharmaceutically active pyrazolo-pyridone modulators of dcn1/2-mediated cullin neddylation
AU2016306558A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
WO2012085003A1 (en) 2-hydroxyisoquinoline-1,3(2h,4h)-diones and related compounds useful as hiv replication inhibitors
CA2526506A1 (en) Inhibitors of papilloma virus
Dobrydnev et al. Synthesis of the First Representatives of Spiro-1λ6-isothiazolidine-1, 1, 4-triones
US9828351B2 (en) Enzyme interacting agents
RS59787B1 (sr) Novo heterociklično jedinjenje, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto
US20150080570A1 (en) Alpha,beta-unsaturated monomers capable of multimerization in an aqueous solution, and methods of using same
CN104016942B (zh) 噻唑啉酮类衍生物及其药物组合物与应用
US20240083873A1 (en) Pyrimidine carboxamide compound and application thereof
CA3199427A1 (en) Compounds for the treatment of acute and chronic kidney disease
JP2009514865A (ja) 有糸分裂キネシン阻害剤
Busujima et al. Identification of 2-[2-(4-tert-Butylphenyl) ethyl]-N-[4-(3-cyclopentylpropyl)-2-fluorophenyl]-1, 2, 3, 4-tetrahydroisoquinoline-6-sulfonamide as an Orally Active MGAT2 Inhibitor
CN106905191B (zh) 一种含有羟肟酸基团的氮芥类化合物及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150407

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160516

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170710